A director at Nokia Corp bought 100,000 shares at 5.374EUR and the significance rating of the trade was 95/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Nokia Corporation - Managers' transactions (Ihamuotila) Nokia CorporationManagers’ transactions30 January 2026 at 17:00 EETNokia Corporation - Managers' transactions (Ihamuotila) Transaction notification under Article 19 of EU Market Abuse Regulation.____________________________________________Person subject to the notification requirementName: Ihamuotila, Timo Position: Member of the Board Issuer: Nokia CorporationLEI: 549300A0JPRWG1KI7U06 Notification type: INITIAL NOTIFICATIONReference number: 140802/5/8 ___________________________________________Transaction date: 2026-01-30Venue: AQ...
Nokia Oyj - Johtohenkilöiden liiketoimet (Ihamuotila) Nokia OyjJohtohenkilöiden liiketoimet30.1.2026 klo 17.00Nokia Oyj - Johtohenkilöiden liiketoimet (Ihamuotila) Markkinoiden väärinkäyttöasetuksen 19. artiklan mukainen ilmoitus liiketoimesta.____________________________________________IlmoitusvelvollinenNimi: Ihamuotila, TimoAsema: Hallituksen jäsen Liikkeeseenlaskija: Nokia CorporationLEI: 549300A0JPRWG1KI7U06Ilmoituksen luonne: ENSIMMÄINEN ILMOITUSViitenumero: 140802/5/8 ____________________________________________Liiketoimen päivämäärä: 2026-01-30Kauppapaikka: AQEAInstrumenttityyppi...
A director at SAP SE bought 6,000 shares at 169.176EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
Press Release: Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Recommendation supported by safety and efficacy results from several clinical studies and real-world evidenceIf approved, Rezurock would offer a new treatment option in the EU for adult patients and in children aged 12 years and older in late line chronic GVHD Paris, January 30, 2026. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a ...
Communiqué de presse : Le CHMP recommande l'approbation du Rezurock de Sanofi dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte Le CHMP recommande l'approbation du Rezurock de Sanofi dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte La recommandation s’appuie sur les résultats de sécurité et d’efficacité de plusieurs études cliniques et par des données en vie réelleS’il est approuvé, Rezurock permettrait d’offrir une nouvelle option thérapeutique dans l’Union européenne (UE) pour les patients adultes et chez les enfants âgés de 12 ans...
Rdos. 4T'25 vs 4T'24: Ventas: 9.684 M euros (+3,3% y +3,5% consenso). EBIT: 2.829 M euros (+16,1% y +12,3% consenso). Rdos. 2025 vs 2024: Ventas: 36.800 M euros (+8% % +8% consenso); EBIT: 10.419 M euros (+28% vs +27%% consenso).
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.